JP2016519110A - 獣医学的デコリン組成物及びそれらの使用 - Google Patents

獣医学的デコリン組成物及びそれらの使用 Download PDF

Info

Publication number
JP2016519110A
JP2016519110A JP2016509148A JP2016509148A JP2016519110A JP 2016519110 A JP2016519110 A JP 2016519110A JP 2016509148 A JP2016509148 A JP 2016509148A JP 2016509148 A JP2016509148 A JP 2016509148A JP 2016519110 A JP2016519110 A JP 2016519110A
Authority
JP
Japan
Prior art keywords
veterinary
decorin
core protein
decorin core
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016509148A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016519110A5 (OSRAM
Inventor
ティー． ブレック，グレゴリー
ティー． ブレック，グレゴリー
Original Assignee
キャタレント ファーマ ソリューションズ リミテッド ライアビリティ カンパニー
キャタレント ファーマ ソリューションズ リミテッド ライアビリティ カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by キャタレント ファーマ ソリューションズ リミテッド ライアビリティ カンパニー, キャタレント ファーマ ソリューションズ リミテッド ライアビリティ カンパニー filed Critical キャタレント ファーマ ソリューションズ リミテッド ライアビリティ カンパニー
Publication of JP2016519110A publication Critical patent/JP2016519110A/ja
Publication of JP2016519110A5 publication Critical patent/JP2016519110A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4725—Proteoglycans, e.g. aggreccan

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2016509148A 2013-04-22 2014-04-22 獣医学的デコリン組成物及びそれらの使用 Pending JP2016519110A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361814405P 2013-04-22 2013-04-22
US61/814,405 2013-04-22
PCT/US2014/034877 WO2014176198A1 (en) 2013-04-22 2014-04-22 Veterinary decorin compositions and use thereof

Publications (2)

Publication Number Publication Date
JP2016519110A true JP2016519110A (ja) 2016-06-30
JP2016519110A5 JP2016519110A5 (OSRAM) 2017-06-15

Family

ID=51729463

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016509148A Pending JP2016519110A (ja) 2013-04-22 2014-04-22 獣医学的デコリン組成物及びそれらの使用

Country Status (6)

Country Link
US (1) US10137168B2 (OSRAM)
EP (1) EP2989208A4 (OSRAM)
JP (1) JP2016519110A (OSRAM)
AU (1) AU2014257267B2 (OSRAM)
CA (1) CA2907944C (OSRAM)
WO (1) WO2014176198A1 (OSRAM)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025515356A (ja) * 2022-04-28 2025-05-14 ジョイント・ストック・カンパニー “バイオキャド” Ｆｖｉｉｉ－ｂｄｄおよび異種シグナルペプチドに基づく融合タンパク質をコードする単離された核酸

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012125626A2 (en) * 2011-03-14 2012-09-20 Catalent Pharma Solutions Llc Decorin compositions and use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5654270A (en) 1988-06-28 1997-08-05 La Jolla Cancer Research Foundation Use of fibromodulin to prevent or reduce dermal scarring
WO1990000194A1 (en) 1988-06-28 1990-01-11 La Jolla Cancer Research Foundation Suppression of cell proliferation by decorin
US6509314B1 (en) * 1988-06-28 2003-01-21 The Burnham Institute Methods of preventing or reducing scarring with decorin or biglycan
US5583103A (en) 1988-06-28 1996-12-10 La Jolla Cancer Research Foundation Inhibition of transforming growth factor beta activity
DE69232946T2 (de) 1991-11-14 2003-12-18 La Jolla Cancer Research Foundation, La Jolla Inhibitoren von zellregulationsfaktoren und verfahren zur verhütung oder verminderung von narbenbildung
US6524573B1 (en) * 1997-12-30 2003-02-25 Thomas Jefferson University Method of suppressing tumor cell growth by administering a decorin gene or gene product
US6673341B2 (en) 1998-07-06 2004-01-06 Beth Israel Deaconness Medical Center Methods of inhibiting proliferative diseases by inhibiting TGF-β-mediated angiogenesis
AU5946501A (en) * 2000-05-05 2001-11-20 Genzyme Transgenics Corp Transgenically produced decorin
US20040033493A1 (en) 2001-01-31 2004-02-19 Tchernev Velizar T. Proteins and nucleic acids encoding same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012125626A2 (en) * 2011-03-14 2012-09-20 Catalent Pharma Solutions Llc Decorin compositions and use thereof

Also Published As

Publication number Publication date
AU2014257267A1 (en) 2015-09-17
AU2014257267B2 (en) 2017-03-16
CA2907944C (en) 2020-11-03
EP2989208A1 (en) 2016-03-02
WO2014176198A1 (en) 2014-10-30
EP2989208A4 (en) 2016-12-07
US10137168B2 (en) 2018-11-27
US20140315806A1 (en) 2014-10-23
CA2907944A1 (en) 2014-10-30

Similar Documents

Publication Publication Date Title
US20220088136A1 (en) Nerve growth factor mutant
CN1087344C (zh) 转化生长因子α－H1
JP2025041910A (ja) ポリリボヌクレオチド及びその化粧用の使用
JP2020532316A (ja) 局所用組成物及び使用
EP2504357A2 (en) Recombinant filaggrin polypeptides for cell importation
JP3990736B2 (ja) 制がん剤
CN107286233B (zh) 低痛神经生长因子突变体
US10137168B2 (en) Veterinary decorin compositions and use thereof
CN1323167C (zh) 1型胎盘生长因子的突变蛋白及其制备方法和应用
EP1080111B1 (en) The induction of antiobiotic peptides by lait (scd14) protein
JPH09511648A (ja) スーパーオキシドジスムターゼ−４
US7091316B2 (en) Protein induced by homogeneous blood transfusion and DNA encoding the same
JP2002523100A (ja) 新規なヒトリゾチーム遺伝子、それによりコードされたポリペプチド、およびそれらの作製方法
KR100406268B1 (ko) 아르기닌 디이미네이즈를 유효성분으로 하는 혈관신생에 의한 질환 치료용 조성물
JP2002523099A (ja) 新規なヒトリゾチーム遺伝子、それによりコードされたポリペプチド、およびそれらの作製方法
EP0686194A1 (fr) Facteurs de croissance de la famille de l'harp, procede d'obtention et applications
US20220088139A1 (en) Nerve growth factor mutant
KR20230059121A (ko) 보툴리눔 유래 펩타이드를 포함하는 통증개선용 조성물
JP4632326B2 (ja) イヌのアトピー性皮膚炎の治療薬及び治療方法
CN120676931A (zh) Engrailed蛋白的稳定水性组合物
WO2004087082A1 (ja) 発毛促進剤組成物
CN115710307A (zh) 蝎毒素及其突变体在抗癫痫中的应用
JP2002532060A (ja) 新規なヒトリゾチーム遺伝子、それによりコードされたポリペプチド、およびそれらの作製方法
JP2001192396A (ja) インターフェロン−γの活性を有するタンパク質の高純度製造法、イヌインターフェロン−γの活性を有する高純度タンパク質、イヌ疾病の治療剤およびイヌ疾病の治療方法
JPWO2000001405A1 (ja) 軟骨細胞の分化促進剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170424

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170424

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180130

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180427

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180730

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20181218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190417

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20190417

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190417

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20190514

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20190521

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20190705

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20190709

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20200114

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20200407

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20200818

C28A Non-patent document cited

Free format text: JAPANESE INTERMEDIATE CODE: C2838

Effective date: 20200818

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20201020

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210118

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20210323

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20210511

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20210511